Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells

被引:25
作者
Liu, Ying [1 ]
Ban, Li-Ying [1 ]
Su, Xi [1 ]
Gao, Shan [1 ]
Liu, Ji-Wei [1 ]
Cui, Xiao-Nan [1 ]
机构
[1] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian 116011, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
cinobufacini injection; HepG-2; cells; proliferation; apoptosis; topoisomerase I; topoisomerase II; PROSTATE-CANCER CELLS; DNA; BUFALIN; APOPTOSIS; HUACHANSU; PATHWAYS; THERAPY; DEATH; PHASE;
D O I
10.3892/mmr.2015.3552
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to investigate the effects of cinobufacini injection on the proliferation and expression of topoisomerases in human HepG-2 hepatocarcinoma cells. The cells were divided into a control group and an experimental group, in which 0.105, 0.21, 0.42 mg/l cinobufacini was injected. Cell proliferation was assessed using a 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide assay, levels of apoptosis were detected using annexin V/propidium iodide staining and cell cycles were analyzed using flow cytometric analysis. The mRNA and protein expression levels of topoisomerase (TOPO) I and TOPO II were determined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. Cinobufacini injection significantly inhibited the proliferation of the HepG-2 cells (P<0.05), induced apoptosis (P<0.05) in a dose- and time-dependent manner, induced tumor cell arrest at the S phase in a dose-dependent manner, and downregulated the mRNA and protein expression levels of TOPO I and TOPO II (P<0.05) in a dose-dependent manner. Therefore, cinobufacini was found to inhibit human HepG-2 hepatocellular carcinoma cell proliferation, and downregulation of the expression levels of TOPO I and TOPO II may contribute to the effect on proliferation observed in the Hep-G(2) cells following cinobbufacini injection.
引用
收藏
页码:1598 / 1604
页数:7
相关论文
共 32 条
[1]  
[Anonymous], J ONCOL
[2]   Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells [J].
Belluti, S. ;
Basile, V. ;
Benatti, P. ;
Ferrari, E. ;
Marverti, G. ;
Imbriano, C. .
CELL DEATH & DISEASE, 2013, 4 :e756-e756
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[5]  
Cui X, 2004, QINGDAO MED J, V36, P434
[6]   Dual topoisomerase I/II inhibitors in cancer therapy [J].
Denny, WA ;
Baguley, BC .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (03) :339-353
[7]   Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters [J].
Fayad, Walid ;
Fryknas, Marten ;
Brnjic, Slavica ;
Olofsson, Maria Haegg ;
Larsson, Rolf ;
Linder, Stig .
PLOS ONE, 2009, 4 (10)
[8]   DNA TOPOISOMERASE-I TARGETED CHEMOTHERAPY OF HUMAN-COLON CANCER IN XENOGRAFTS [J].
GIOVANELLA, BC ;
STEHLIN, JS ;
WALL, ME ;
WANI, MC ;
NICHOLAS, AW ;
LIU, LF ;
SILBER, R ;
POTMESIL, M .
SCIENCE, 1989, 246 (4933) :1046-1048
[9]  
Gong Z. P., 2010, CHIN J EXP TRADIT ME, V16, P120
[10]  
Hofland K, 2000, CLIN CANCER RES, V6, P1488